#United States #Salt Lake City #Shed #LTR Pharma #ROXUS®

Shed and LTR Pharma Join Forces for ROXUS® Commercialization

In a landmark agreement announced on July 21, 2026, Shed has finalized a commercial partnership with LTR Pharma to introduce ROXUS®, a groundbreaking treatment for erectile dysfunction (ED). This innovative therapy, delivered intranasally, is poised to revolutionize how ED is managed, offering patients an alternative with rapid onset compared to traditional oral medications.

A New Era of ED Treatment

The collaboration turns a previously binding term sheet into a solid operational framework, which will enable Shed to leverage its telehealth platform and specialized men's health brand, Mavrox, to effectively launch ROXUS® throughout the United States. This strategic move aligns with Shed's broader mission to enhance access to effective and clinically significant treatments, promoting innovative solutions through modern telemedicine practices.

Under the terms of this partnership, Shed will oversee crucial aspects such as patient acquisition, clinical operations, and commercialization efforts, while LTR Pharma will contribute its advanced intranasal treatment technologies. These collaborative efforts will ensure a streamlined launch process for ROXUS®, marking an important step in transforming men's health care.

Innovative Treatment with Rapid Onset

ROXUS® is positioned to be one of the first significant innovations in the ED treatment landscape in recent years. The intranasal delivery system is designed for rapid action, with the potential to offer results in as little as five minutes. This is a considerable improvement over traditional treatment methods, empowering patients with more immediate options.

Morley Baker, CEO of Shed and Mavrox, expressed enthusiasm over the partnership stating, “We are excited to formally announce our agreement with LTR Pharma. ROXUS is genuinely different in a market that has seen little innovation in recent times. The fast-acting intranasal method could lead to significant customer success.”

Mavrox will prominently feature ROXUS® as its flagship product, solidifying its commitment to aiding men in optimizing their health with evidence-based approaches.

Comprehensive Patient Support

Shed has built a reputation as one of America’s leading direct-to-consumer telehealth services, expanding its focus areas to include a range of health-related issues. With the addition of ROXUS®, Shed strengthens its men's health portfolio significantly. The services provided will integrate licensed health professionals, ensuring patients receive personalized, medically sound support throughout their treatment process.

Preparations for the commercial roll-out of ROXUS® are currently underway. The product is already listed on the Mavrox platform, with an early-access patient waitlist in place as the companies finalize the logistics and regulatory processes necessary for its launch.

About Shed and Mavrox

Shed is renowned for offering personalized and clinically guided care aimed at fostering long-term wellness. Its approach combines licensed healthcare providers with technology-driven solutions to target weight management, sexual health, and preventative wellness, among others. This partnership with LTR Pharma is a natural extension of Shed’s dedication to delivering cutting-edge health solutions more efficiently than traditional health systems allow.

Mavrox serves as the consumer interface for men's health products under Shed’s umbrella, facilitating easy access to healthcare services that resonate with male consumers. Both platforms aim to support and empower men in their health journeys, ensuring they can receive timely and effective treatments such as ROXUS®.

ROXUS® represents an exciting development in how we can address ED, creating new pathways for therapeutic interventions that meet the evolved expectations of today’s patients.

Future Implications

As Shed moves forward with its launch strategies, both companies remain optimistic about the impact of ROXUS® on ED treatment. With the potential to enhance patient experience significantly, this agreement highlights the shift towards more accessible and innovative care solutions in healthcare today. It sets the stage for what could be a transformative period for men’s health services in the United States.

For more information on ROXUS® and the services offered through Mavrox, consumers can visit Mavrox.com.